David Milligan - Madrigal Pharmaceuticals Independent Director
| MDGL Stock | USD 194.38 10.27 5.02% |
Director
Dr. David V. Milligan, Ph.D., is an Independent Director of Madrigal Pharmaceuticals Inc, since July 2016. Dr. Milligan currently works as an independent consultant. Previously, Dr. Milligan was a partner at Bay City Capital, LLC, a life sciences investment firm, a position he held from 1997 through 2013. From 1979 to 1996, Dr. Milligan served as Senior Vice President and Chief Scientific Officer at Abbott Laboratories, a publiclyheld life sciences company. Dr. Milligan currently serves as a director of Inspirotech and Xoult, both privatelyheld life sciences companies. During the past five years, Dr. Milligan has served as a director of Caliper Life Sciences, a publiclyheld pharmaceutical and biotechnology company that was acquired by PerkinElmer Company, and served as a director of WebLOQ, Inc. a privatelyheld information technology security company. Dr. Milligan also served as Chairman and a director at Vicuron Pharmaceuticals, Inc., a privatelyheld biopharmaceutical company acquired by Pfizer, from 1997 to 2005, as a director of Reliant Pharmaceuticals, Inc., a privatelyheld pharmaceutical company acquired by GlaxoSmithKline, from 1999 to 2007, as a director of Pathway Diagnostics Corporationrationration, a privatelyheld diagnostics company acquired by Quest Diagnostics, Inc., from 2002 to 2008, as a director of ICOS Corporationrationration, a publiclyheld pharmaceutical company acquired by Eli Lilly, from 1995 to 2007, and as a director of Maxia Pharmaceuticals, Inc., a privatelyheld pharmaceutical company acquired by Incyte Corporationrationration, from 1999 to 2003 since 2016.
| Age | 77 |
| Tenure | 8 years |
| Address | Four Tower Bridge, West Conshohocken, PA, United States, 19428 |
| Phone | 267 824 2827 |
| Web | https://www.madrigalpharma.com |
Madrigal Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4741) % which means that it has lost $0.4741 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2398) %, meaning that it created substantial loss on money invested by shareholders. Madrigal Pharmaceuticals' management efficiency ratios could be used to measure how well Madrigal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.61. The value of Return On Capital Employed is expected to slide to -0.77. At this time, Madrigal Pharmaceuticals' Total Assets are quite stable compared to the past year. Other Current Assets is expected to rise to about 3.3 M this year, although the value of Non Currrent Assets Other will most likely fall to about 719.9 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Lawson Macartney | Viking Therapeutics | 60 | |
| Alan Howarth | Terns Pharmaceuticals | 69 | |
| Josh Suskin | Krystal Biotech | N/A | |
| Athena Countouriotis | Iovance Biotherapeutics | 46 | |
| Ronald Renaud | PTC Therapeutics | 45 | |
| Glenn Steele | PTC Therapeutics | 73 | |
| Deepa Pakianathan | Mereo BioPharma Group | 53 | |
| Yann Echelard | TG Therapeutics | 54 | |
| Timothy Block | Hepion Pharmaceuticals | 61 | |
| Laurence Charney | TG Therapeutics | 71 | |
| Kathleen Behrens | Sarepta Therapeutics | 65 | |
| Claude Nicaise | Sarepta Therapeutics | 65 | |
| Michael Weiser | Iovance Biotherapeutics | 55 | |
| Michael Wyzga | Mereo BioPharma Group | 63 | |
| Kathy Rouan | Viking Therapeutics | 56 | |
| Stephen Webster | Viking Therapeutics | 57 | |
| Rene Russo | X4 Pharmaceuticals | 42 | |
| Emma Reeve | PTC Therapeutics | 57 | |
| Michael Bonney | Sarepta Therapeutics | 59 | |
| Adam Koppel | PTC Therapeutics | 45 | |
| Richard Barry | Sarepta Therapeutics | 59 | |
Management Performance
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.47 |
Madrigal Pharmaceuticals Leadership Team
Elected by the shareholders, the Madrigal Pharmaceuticals' board of directors comprises two types of representatives: Madrigal Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Madrigal. The board's role is to monitor Madrigal Pharmaceuticals' management team and ensure that shareholders' interests are well served. Madrigal Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Madrigal Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Hare, Senior Management | ||
| Remy Sukhija, VP Officer | ||
| Mardi Dier, Principal CFO | ||
| David Milligan, Independent Director | ||
| Richard Levy, Director | ||
| PharmD MBA, Senior Affairs | ||
| Chen Schor, President CEO, Director | ||
| William Sibold, President CEO | ||
| Ronald Filippo, Chief Officer | ||
| William Reardon, Independent Director | ||
| Paul MD, Chairman CEO | ||
| Edward Chiang, Senior Operations | ||
| Clint Wallace, Chief Officer | ||
| James Daly, Independent Director | ||
| Bruce Kovner, Independent Director | ||
| Alex Howarth, Executive Officer | ||
| Frederick Craves, Lead Independent Director | ||
| Paul Friedman, Independent Director | ||
| Rebecca Taub, Founder, Chief Medical Officer, Executive Vice President Research & Development and Director | ||
| Marc Schneebaum, CFO, Senior Vice President | ||
| Robert Wilson, Independent Director | ||
| Donald Kufe, Independent Director | ||
| Kenneth Bate, Director | ||
| Rebecca MD, Chief Founder | ||
| Robert Waltermire, Chief Officer | ||
| Scott Morenstein, Director | ||
| Wendy Rieder, Senior Vice President General Counsel | ||
| Keith Gollust, Chairman of the Board | ||
| Tina Ventura, Chief Officer | ||
| Kianoush Motesharei, Senior Development | ||
| Brian JD, Senior Counsel |
Madrigal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Madrigal Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 3.56 B | ||||
| Shares Outstanding | 20.97 M | ||||
| Shares Owned By Insiders | 9.24 % | ||||
| Shares Owned By Institutions | 94.86 % | ||||
| Number Of Shares Shorted | 3.41 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 12.24 X | ||||
| EBITDA | (379.97 M) |
Madrigal Pharmaceuticals Investors Sentiment
The influence of Madrigal Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Madrigal. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Madrigal Pharmaceuticals' public news can be used to forecast risks associated with an investment in Madrigal. The trend in average sentiment can be used to explain how an investor holding Madrigal can time the market purely based on public headlines and social activities around Madrigal Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Madrigal Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Madrigal Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Madrigal Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Madrigal Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Madrigal Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Madrigal Pharmaceuticals' short interest history, or implied volatility extrapolated from Madrigal Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.Note that the Madrigal Pharmaceuticals information on this page should be used as a complementary analysis to other Madrigal Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Madrigal Stock analysis
When running Madrigal Pharmaceuticals' price analysis, check to measure Madrigal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Madrigal Pharmaceuticals is operating at the current time. Most of Madrigal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Madrigal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Madrigal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Madrigal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Madrigal Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.99) | Return On Assets (0.47) | Return On Equity (1.24) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.